AbbVie Inc (ABBV)vsOncology Institute Inc (TOI)
ABBV
AbbVie Inc
$258.09
-1.81%
HEALTHCARE · Cap: $442.36B
TOI
Oncology Institute Inc
$5.13
+5.56%
HEALTHCARE · Cap: $512.91M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11697% more annual revenue ($64.39B vs $545.76M). ABBV leads profitability with a 9.8% profit margin vs -8.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.9%
Fair Value
$151.49
Current Price
$258.08
$106.59 premium
Margin of Safety
+22.9%
Fair Value
$3.40
Current Price
$5.13
$1.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Revenue surging 41.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -652.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 70.5x leaves little room for execution misses.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while TOI is a hypergrowth play — different risk/reward profiles.
TOI carries more volatility with a beta of 0.42 — expect wider price swings.
TOI is growing revenue faster at 41.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 45/100) and 10.2% revenue growth. TOI offers better value entry with a 22.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling investment opportunity within the dynamic healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?